CAR-T Clinical Trial Registry in China
June 2026 Update
China is the world's largest CAR-T trial ecosystem, with more than a thousand registered studies and a rapidly expanding clinical pipeline. This registry helps patients, caregivers, and referring physicians identify currently relevant CAR-T trials by NCT number, hospital, eligibility, and enrollment status.
Why This Registry Matters
Most patients searching for CAR-T in China do not need a generic explanation of CAR-T. They need to know whether a trial exists for their diagnosis, where it is running, and what kind of patient the study accepts. This registry reduces noise by focusing on practical access questions: trial identity, location, eligibility, and current status.
A global multidimensional analysis reported that China has the largest CAR-T trial footprint, with 1,006 trials compared with 549 in the United States, accounting for more than 80% of the global total together with the US. That makes China the most important geography to monitor for CAR-T trial access — especially for patients who may not qualify for commercial therapy or who need a trial pathway.
How to Use This Page
- Find your cancer type using the jump links below the registry table.
- Check whether the trial is recruiting. Status is labeled as Recruiting, Active, or Registered.
- Confirm age, disease stage, and prior-treatment requirements in the eligibility summary.
- Review hospital location and logistics.
- Send the case for eligibility review if a trial appears to match.
Active CAR-T Trials in China
Each row is linked to its official ClinicalTrials.gov or ChiCTR entry. Last verified: June 2026.
B-Cell Malignancies
| NCT / Registry ID | Trial Title | Cancer Type | Hospital / City | Status | Key Eligibility | Source |
|---|---|---|---|---|---|---|
| NCT03952923 | CD19-CAR-T in B-cell Malignancies Patients | B-cell hematologic malignancies | China site(s) | Recruiting | Relapsed/refractory CD19+ disease; ages 1–70; ECOG 0–3 | ClinicalTrials.gov → |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells | B-cell NHL, B-ALL, MM | China site(s) | Registered | Relapsed/progressive disease; organ function thresholds apply | ClinicalTrials.gov → |
| NCT07558850 | Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T | Not oncology-specific in listing | Nanjing, Jiangsu, China | Recruiting | Hospital site listed in registry | Registry → |
Multiple Myeloma
| NCT / Registry ID | Trial Title | Cancer Type | Hospital / City | Status | Key Eligibility | Source |
|---|---|---|---|---|---|---|
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells (MM arm) | Multiple Myeloma | China site(s) | Registered | Relapsed/progressive MM; prior therapy requirements apply | ClinicalTrials.gov → |
Other Indications
| NCT / Registry ID | Trial Title | Cancer Type | Hospital / City | Status | Key Eligibility | Source |
|---|---|---|---|---|---|---|
| NCT06733610 | CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA | Autoimmune hemolytic anemia | China site(s) | Active | Adult patients; organ-function thresholds apply | ClinicalTrials.gov → |
What CAR-T Trials Typically Require
Disease Type
Most trials focus on B-cell hematologic malignancies (DLBCL, B-ALL, Multiple Myeloma). A growing number of trials target autoimmune conditions and solid tumors — but hematologic indications remain the dominant category.
Prior Therapy Requirements
Typically, patients must have relapsed after or been refractory to at least 2 prior lines of standard therapy. Some trials accept patients after 1 prior line if the disease is high-risk.
Age Range
Most trials accept patients aged 1–70, though pediatric-specific and adult-specific trials exist. Check each trial's inclusion criteria for exact age limits.
Performance Status
ECOG 0–2 is typical. Some trials accept ECOG 3 on a case-by-case basis. ECOG 4 is generally an exclusion criterion.
Antigen Requirement
CD19-targeted trials require confirmed CD19 expression on tumor cells. BCMA-targeted trials require confirmed BCMA expression. Dual-target trials (CD19/BCMA) may accept either or both.
Organ Function Thresholds
Most trials require adequate hepatic, renal, cardiac, and pulmonary function. Exact thresholds vary by protocol — check the specific trial's inclusion criteria.
Hospital and Logistics Information
For each trial in the registry above, the following logistics factors should be confirmed directly with the trial site before travel:
- Hospital name and city — listed in the registry table where available.
- Whether the site accepts international patients — not all Chinese CAR-T trial sites do; confirm before making travel arrangements.
- Expected screening time — typically 1–2 weeks from document submission to eligibility confirmation.
- Sample or pathology needs — most trials require tissue blocks, pathology slides, and recent imaging. Some require fresh tissue for antigen confirmation.
- Estimated wait time — from eligibility confirmation to treatment initiation, typically 2–4 weeks depending on manufacturing slot availability.
Who This Registry Is For
🩺 For Patients and Caregivers
This registry is for people who want to know whether a CAR-T trial in China might fit their case without spending hours searching fragmented trial pages. If your cancer is a hematologic malignancy and standard treatments have failed, China may offer trial options that are not easily available elsewhere.
👨⚕️ For Referring Physicians
Use this page as a screening reference, not as the final source of eligibility. Always confirm current status directly with the trial site before referral, because registry entries may lag behind institutional changes. Both ClinicalTrials.gov and Chinese registry sources (ChiCTR) are monitored for updates.
Frequently Asked Questions
This registry is updated monthly. Each row is checked against ClinicalTrials.gov and ChiCTR for status changes, new trials, and enrollment updates. The "Last updated" date at the top of the page reflects the most recent verification cycle.
Not all of them. Some Chinese CAR-T trial sites accept international patients; others are restricted to domestic enrollment. This must be confirmed directly with the trial site before travel arrangements are made. The registry flags international accessibility where that information is publicly available.
Check the eligibility summary box for general requirements, then review the specific trial's inclusion and exclusion criteria on ClinicalTrials.gov or ChiCTR. Key factors include: diagnosis, prior therapy history, age, ECOG performance status, organ function, and antigen expression (CD19, BCMA, or both). If a trial appears to match, submit your case for a structured eligibility review.
Most trial sites require: pathology report confirming diagnosis and antigen expression, recent imaging (PET-CT or CT), treatment history summary, current lab results (CBC, liver and kidney function), and ECOG performance status documentation. Some trials also require tissue blocks or fresh biopsy material for confirmatory testing.
Yes. Both ClinicalTrials.gov and the Chinese Clinical Trial Registry (ChiCTR) are monitored for this page. Dual-registered trials are preferred because dual registration is a hallmark of rigorous, internationally compliant studies. When a trial is registered in both databases, both identifiers are listed.
This page focuses on clinical trials and Investigator-Initiated Trials (IITs). Commercial, NMPA-approved CAR-T products (available out-of-pocket at Chinese hospitals) are covered on our CAR-T Therapy page and our China Access Pathways page. The distinction matters because commercial access and trial access have very different eligibility requirements and cost structures.
Need Help Checking Whether Your Case Matches an Active CAR-T Trial in China?
Send the diagnosis, pathology, prior treatment history, age, and country of residence for structured review. Our team will cross-reference your profile against the current trial landscape and respond within 48 hours.